RNAZ

TransCode

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 2

Sell signal 1

stock price surged significantly

consensus rating "Strong Buy"

EPS Below Expectations

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About RNAZ

Transcode Therapeutics, Inc.

An oncology based biotech company that develops RNA therapeutics for the treatment of tumor

Industry

Biological Technology

Established Date

01/11/2016

Listing Date

07/09/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.transcodetherapeutics.com

Security Type

Common stock

Office address

6 Liberty Square, #2382, Boston, MA 02109

Business

Introduction

TransCode Therapeutics, Inc., was incorporated under the laws of the State of Delaware on January 11, 2016. The company is an RNA oncology company founded on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapies. RNA-based therapies are highly selective for their targets and have the potential to provide a range of targets in the human genome that were previously untreatable with drugs.

Company Financials

EPS

RNAZ has released its 2023 Q3 earnings. EPS was reported at -67.20, versus the expected -1.50, missing expectations. The chart below visualizes how RNAZ has performed over recent quarters, highlighting trends in earnings surprises.